A clinical study of nafazatrom in advanced human breast cancer

Cancer Chemother Pharmacol. 1991;27(4):326-8. doi: 10.1007/BF00685120.

Abstract

Prostaglandins (PGs) have been shown to inhibit tumour metastases in experimental animal systems. Nafazatrom is a pyrazolinone derivative that increases endogenous prostacyclin (PGI2) and has experimental anti-cancer activity. In the present study, nafazatrom was given to 47 women with advanced breast cancer; objective remission of metastases was seen in 2 patients and stabilisation of disease in 1 case. Nafazatrom was safe and well tolerated.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Drug Evaluation
  • Female
  • Humans
  • Middle Aged
  • Prostaglandins / biosynthesis
  • Pyrazoles / adverse effects
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use*
  • Pyrazolones*

Substances

  • Antineoplastic Agents
  • Prostaglandins
  • Pyrazoles
  • Pyrazolones
  • nafazatrom